在基因治疗与基因编辑时代定义输血依赖型β地中海贫血的治愈终点
输血依赖型β地中海贫血(TDT)以无效造血和需终身规律输血为特征,可致铁过载、终末器官损伤和早亡风险。基因添加与基因编辑疗法有望提供一次性功能性治愈,但试验设计的关键挑战在于选择能区分治愈与缓解效果的终点。本文概述TDT病理生理、综述在研基因治疗途径,并提出可量化疗效(包括治愈结局)的系列终点。
要点
- TDT需终身规律输血,可致铁过载、终末器官损伤和早亡风险。
- 除异基因造血细胞移植外,现有治疗仅对症,不针对病因。
- 基因添加与基因编辑疗法有望一次性功能性治愈,试验终点选择是关键挑战。
核心结论
- 基因添加与基因编辑疗法有望为TDT提供一次性功能性治愈,试验设计的关键挑战是选择能区分治愈与缓解效果的终点。
- 本文提出一系列可量化疗效(包括治愈结局)的终点。
研究设计与样本
- 本文为综述,概述TDT病理生理、综述在研基因添加或基因编辑治疗途径,并提出可量化疗效的终点。
主要发现
- TDT为单基因病,最严重形式以无效造血和需终身规律红细胞输注为临床标志,并出现铁过载、终末器官损伤和早亡风险等继发临床并发症。
- 除异基因造血细胞移植外,当前TDT治疗针对疾病症状而非病因。
- 越来越多基因添加和基因编辑疗法进入临床试验,有望提供一次性功能性治愈。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
β-thalassemia is a monogenic disease that results in varying degrees of anemia. In the most severe form, known as transfusion-dependent β-thalassemia (TDT), the clinical hallmarks are ineffective erythropoiesis and a requirement of regular, life-long red blood cell transfusions, with the development of secondary clinical complications such as iron overload, end-organ damage, and a risk of early mortality. With the exception of allogeneic hematopoietic cell transplantation, current treatments for TDT address disease symptoms and not the underlying cause of disease. Recently, a growing number of gene addition and gene editing-based treatments for patients with TDT with the potential to provide a one-time functional cure have entered clinical trials. A key challenge in the design and evaluation of these trials is selecting endpoints to evaluate if these novel genetic therapies have a curative versus an ameliorative effect. Here, we present an overview of the pathophysiology of TDT, review emerging gene addition or gene editing therapeutic approaches for TDT currently in clinical trials, and identify a series of endpoints that can quantify therapeutic effects, including a curative outcome.
引用
- Corbacioglu S, Frangoul H, Locatelli F, et al. Defining curative endpoints for transfusion-dependent β-thalassemia in the era of gene therapy and gene editing. Am J Hematol. 2023. PMID: 38100154. doi:10.1002/ajh.27166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。